» Articles » PMID: 15574420

A Novel Role for Gab1 and SHP2 in Epidermal Growth Factor-induced Ras Activation

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2004 Dec 3
PMID 15574420
Citations 91
Authors
Affiliations
Soon will be listed here.
Abstract

SHP2 was recently found to down-regulate PI3K activation by dephosphorylating Gab1 but the mechanisms explaining the positive role of the Gab1/SHP2 pathway in EGF-induced Ras activation remain ill defined. Substrate trapping experiments now suggest that SHP2 dephosphorylates other Gab1 phosphotyrosines located within a central region displaying four YXXP motifs. Because these sites are potential docking motifs for Ras-GAP, we tested whether SHP2 dephosphorylates them to facilitate Ras activation. We observed that a Gab1 construct preventing SHP2 recruitment promoted membrane relocation of RasGAP. Moreover, a RasGAP-inactive mutant restored the activation of Ras in cells transfected with SHP2-inactivating Gab1 mutant or in SHP2-deficient fibroblasts, supporting the hypothesis that RasGAP is a downstream target of SHP2. To determine whether Gab1 is a RasGAP-binding partner, a Gab1 mutant deleted of four YXXP motifs was produced. The deletion suppressed RasGAP redistribution and restored the defective Ras activation caused by SHP2-inactivating mutations. Moreover, Gab1 was found to interact with RasGAP SH2 domains, only under conditions where SHP2 is not activated. To identify Ras-GAP-binding sites, Tyr to Phe mutants of Gab1 YXXP motifs were produced. Gab1 constructs mutated on Tyr(317) were severely affected in RasGAP binding and were the most active in compensating for Ras-defective activation and blocking RasGAP redistribution induced by SHP2 inactivation. We have thus localized on Gab1 a Ras-negative regulatory tyrosine phosphorylation site involved in RasGAP binding and showed that an important SHP2 function is to down-regulate its phosphorylation to disengage RasGAP and sustain Ras activation.

Citing Articles

Allosteric inhibition rescues hydrocephalus caused by catalytically inactive Shp2.

Makrides N, Sun E, Mir H, Jiang Z, Wu Y, Serra C bioRxiv. 2025; .

PMID: 39974929 PMC: 11838390. DOI: 10.1101/2025.01.28.635289.


Targeting Shp2 as a therapeutic strategy for neurodegenerative diseases.

Pang J, Cen C, Tian Y, Cao X, Hao L, Tao X Transl Psychiatry. 2025; 15(1):6.

PMID: 39794316 PMC: 11724000. DOI: 10.1038/s41398-024-03222-1.


Tyrosine phosphatase SHP2 promoted the progression of CRC via modulating the PI3K/BRD4/TFEB signaling induced ferroptosis.

Chen J, Li W, Zhang C, Wen D, Jiao C Discov Oncol. 2024; 15(1):793.

PMID: 39692787 PMC: 11655821. DOI: 10.1007/s12672-024-01586-w.


The MET Oncogene: An Update on Targeting Strategies.

Gallo S, Folco C, Crepaldi T Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598385 PMC: 11597589. DOI: 10.3390/ph17111473.


Targeting Grb2 SH3 Domains with Affimer Proteins Provides Novel Insights into Ras Signalling Modulation.

Tang A, MacDonald A, McPherson M, Tomlinson D Biomolecules. 2024; 14(8).

PMID: 39199427 PMC: 11352564. DOI: 10.3390/biom14081040.